Safety, tolerability and sensory evaluation of Liv.52 DS SF Syrup in healthy volunteers

Himalaya Wellness Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•Adult population:
•1.Healthy adult subjects of either sex aged between Ã¢â?°Â¥ 18 to Ã¢â?°Â¤ 50 years.
•2.Subjects willing to refrain taking any other similar medication during the study period
•3.Adult subjects who have not participated in this kind of trial in the past 4 weeks
•4.Adult subjects willing to sign informed consent and follow the study procedure.
•Pediatric Population:
•1.Healthy male and female pediatric subjects aged between Ã¢â?°Â¥2 years to Ã¢â?°Â¤12 years.
•2.Parents/Guardians/Caregiver related to pediatric subjects < 7 years willing to give informed consent for his/her child to participate in the study.
•3.Pediatric subjects aged > 7 years of age willing to provide oral consent for his/her participation in the study along with parents/guardians/caregiver consent (Refer protocol section 11.4, Informed Consent Process)
•4.Pediatric Subjects willing to refrain taking any other similar medication during the study period
•5.Pediatric subjects who have not participated in this kind of trial in the past 4 weeks.
•6.Parents/ Guardians/ Caregivers of the pediatric subjects willing to sign informed consent/assent (as applicable) and follow the study procedure.

•1.Subjects with clinically significant serious cardiovascular, respiratory, cerebrovascular, hepatic, renal disease, endocrinal, congenital or any other disorder.
•2.A known history or present condition of allergic response to the study products its components or ingredients in the investigational product.
•3.Pre-existing systemic disease necessitating long-term medications.
•4.Subjects who refused to sign informed consent.
•5.Pregnant and lactating women.

发起方